epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLC10.17749/2077-8333.2019.11.4.364-378epilepsia-503Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИPharmacogenetics of carbamazepineФармакогенетика карбамазепинаhttps://orcid.org/0000-0002-2840-837XШнайдерН. А.ShnayderN. A.

Шнайдер Наталья Алексеевна – д.м.н., проф., ведущий научный сотрудник отделения персонализированной психиатрии и неврологии 

Elibrary ID: 185359; SPIN-код: 6517-0279; Researcher ID: M-7084-2014; Scopus ID: 24503222300

Natalia A. Shnayder – MD, PhD, Professor, Leading Researcher, Department of Personalized Psychiatry and Neurology, Bechterev National Medical Research Center of Psychiatry and Neurology. Elibrary ID: 185359; SPIN-код: 6517-0279; Researcher ID: M-7084- 2014; Scopus ID: 24503222300

naschnaider@yandex.ruhttps://orcid.org/0000-0003-4371-2342БочановаЕ. Н.BochanovaE. N.

Бочанова Елена Николаевна – д.м.н., врач – консультант отделения персонализированной психиатрии и неврологии 

доцент кафедры фармакологии и фармацевтического консультирования с курсом 

Elibrary ID: 752926; SPIN-код: 2572- 0525; Researcher ID: V-9286-2018

Elena N. Bochanova – MD, PhD, Consulting Physician, Department of Personalized Psychiatry and Neurology, Bechterev National Medical Research Center of Psychiatry and Neurology, Associate Professor at the Department of Pharmacology, VoinoYasenetsky State Medical University, City of Krasnoyarsk. Elibrary ID: 752926; SPIN-код: 2572-0525; Researcher ID: V-9286- 2018

https://orcid.org/0000-0003-4639-6365ДмитренкоД. В.DmitrenkoD. V.

Дмитренко Диана Викторовна – д.м.н., руководитель Неврологического центра эпилептологии, нейрогенетики Университетской клиники, заведующая кафедрой медицинской генетики и клинической нейрофизиологии 

Elibrary ID: 614958; SPIN-код: 9180-6623; Researcher ID: H-7787-2016; Scopus ID: 55413907300

Diana V. Dmitrenko – MD, PhD, Head of the Neurological Center for Epileptology and Neurogenetics, Head of the Department of Medical Genetics and Clinical Neurophysiology, IPO, Voino-Yasenetsky State Medical University, City of Krasnoyarsk. Elibrary ID: 614958; SPIN-код: 9180-6623; Researcher ID: H-7787-2016; Scopus ID: 55413907300

https://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

Насырова Регина Фаритовна – д.м.н., главный научный сотрудник отделения персонализированной психиатрии и неврологии 

Elibrary ID: 551543; SPIN-код: 3799-0099; Researcher ID: B-1259-2014; Scopus ID: 15769218400

Regina F. Nasyrova – MD, PhD, Chief Scientist, Head of the Department of Personalized Psychiatry and Neurology, Bechterev National Medical Research Center of Psychiatry and Neurology. Elibrary ID: 551543; SPIN-код: 3799-0099; Researcher ID: B-1259-2014; Scopus ID: 15769218400

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Министерства здравоохранения Российской ФедерацииРоссияBekhterev National Medical Research Center of Psychiatry and NeurologyRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской ФедерацииРоссияBekhterev National Medical Research Center of Psychiatry and Neurology; Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской ФедерацииРоссияProf. V. F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation201911012020114364378Copyright © Shnayder N.A., Bochanova E.N., Dmitrenko D.V., Nasyrova R.F., 20202020Шнайдер Н.А., Бочанова Е.Н., Дмитренко Д.В., Насырова Р.Ф.Shnayder N.A., Bochanova E.N., Dmitrenko D.V., Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/503

Carbamazepine (CMZ) is a drug from the group of anticonvulsants, similar in chemical structure to tricyclic antidepressants. CMZ is widely used for mental disorders and neurological diseases. The lecture discusses the safety of CMZ in respect to personalized medicine, while considering the pharmacogenetic profile of the patient.

The authors declare about the absence of conflict of interest with respect to this publication. All authors contributed equally to this article.

Карбамазепин (КМЗ) – препарат из группы антиконвульсантов, близкий по химической структуре к трициклическим антидепрессантам. КМЗ широко применяется при психических расстройствах и неврологических заболеваниях. В лекции рассматриваются вопросы безопасности применения КМЗ с позиции персонализированной медицины, учитывающей особенности фармакогенетического профиля пациента.

Авторы заявляют об отсутствии конфликта интересов в отношении данной публикации. Все авторы сделали эквивалентный вклад в подготовку публикации.

карбамазепинэффективностьбезопасностьнежелательная побочная реакцияфармакогенетикафармакокинетикафармакодинамикаcarbamazepineefficacysafetyadverse drug reactionpharmacogeneticspharmacokineticspharmacodynamicsReferencesМазо Г.Э., Липатова Л.В., Жуков Н.Э. Расстройства биполярного спектра при эпилепсии. Журнал Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2016; 3: 30-40.Mazo G. E., Lipatova L.V., Zhukov N. E. Disorders of the bipolar spectrum in epilepsy. Zhurnal Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva (in Russ.). 2016; 3: 30-40.Harris M., Chandran S., Chakraborty N., Healy D. Mood-stabilizers: the archeology of the concept. Bipolar Disord. 2003; 5 (6): 446-452.Harris M., Chandran S., Chakraborty N., Healy D. Mood-stabilizers: the archeology of the concept. Bipolar Disord. 2003; 5 (6): 446-452.Amann B., Grunze H., Vieta E., Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci. 2007; 38 (2): 116-123. DOI: 10.1177/155005940703800214.Amann B., Grunze H., Vieta E., Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci. 2007; 38 (2): 116-123. DOI: 10.1177/155005940703800214.Schindler W., Häfliger F. Über Derivate des Iminodibenzyls. Helvetica Chimica Acta. 1954; 37 (2): 472-483.Schindler W., Häfliger F. Über Derivate des Iminodibenzyls. Helvetica Chimica Acta. 1954; 37 (2): 472-483.Okuma T., Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosc. 1998; 52 (1): 3-12.Okuma T., Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosc. 1998; 52 (1): 3-12.Sardar K., Rashid M.A., Khandoker M.R., Khan A.N. Anticonvulsants and antidepressants in chronic pain management. J Recent Adv Pain. 2016; 2 (3): 90-93. DOI: 10.5005/jp-journals-10046-0050.Sardar K., Rashid M.A., Khandoker M.R., Khan A.N. Anticonvulsants and antidepressants in chronic pain management. J Recent Adv Pain. 2016; 2 (3): 90-93. DOI: 10.5005/jp-journals-10046-0050.Pearce R. E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metabolism and Disposition. 2002; 30 (11): 1170-1179. DOI: 10.1124/dmd.30.11.1170.Pearce R. E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metabolism and Disposition. 2002; 30 (11): 1170-1179. DOI: 10.1124/dmd.30.11.1170.Bielen I., Sruk A, Planjar-Prvan M., et al. Age-related pattern of the antiepileptic drug utilization in active epilepsy: a population-based survey. Coll Antropol. 2009; 33 (2): 659-663.Bielen I., Sruk A, Planjar-Prvan M., et al. Age-related pattern of the antiepileptic drug utilization in active epilepsy: a population-based survey. Coll Antropol. 2009; 33 (2): 659-663.Albsoul-Younes A., Gharaibeh L., Murtaja A.A., et al. Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan. Neurosciences (Riyadh). 2016; 21 (3): 264-267. DOI: 10.17712/ nsj.2016.3.20150766.Albsoul-Younes A., Gharaibeh L., Murtaja A.A., et al. Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan. Neurosciences (Riyadh). 2016; 21 (3): 264-267. DOI: 10.17712/ nsj.2016.3.20150766.Habib M., Khan S.U., Hoque A., et al. Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital. BMC Res Notes. 2013; 6: 473. DOI: 10.1186/1756-0500-6-473.Habib M., Khan S.U., Hoque A., et al. Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital. BMC Res Notes. 2013; 6: 473. DOI: 10.1186/1756-0500-6-473.Cohen S.A., Lawson J.A., Graudins L.V., et al. Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines. J Paediatr Child Health. 2012; 48 (6): 490-495.Cohen S.A., Lawson J.A., Graudins L.V., et al. Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines. J Paediatr Child Health. 2012; 48 (6): 490-495.Landmark C. J., Fossmark H., Larsson P.G., et al. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011; 95 (1-2): 51-59. DOI: 10.1016/j. eplepsyres.2011.02.012.Landmark C. J., Fossmark H., Larsson P.G., et al. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011; 95 (1-2): 51-59. DOI: 10.1016/j. eplepsyres.2011.02.012.Kwong K. L., Tsui K.W., Wu S.P., et al. Utilization of antiepileptic drugs in Hong Kong children. Pediatr Neurol. 2012; 46 (5): 281-286. DOI: 10.1016/j.pediatrneurol.2012.02.019.Kwong K. L., Tsui K.W., Wu S.P., et al. Utilization of antiepileptic drugs in Hong Kong children. Pediatr Neurol. 2012; 46 (5): 281-286. DOI: 10.1016/j.pediatrneurol.2012.02.019.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729–744. DOI: 10.1007/s13318-016-0397-3.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729–744. DOI: 10.1007/s13318-016-0397-3.Бочанова Е.Н., Шнайдер Н.А., Зырянов С.К., Дмитренко Д.В., Журавлев Д.А., Ноздрачев К. Г., Богданов В.В., Веселова О.Ф. Оценка потребления противоэпилептических препаратов в амбулаторной практике. Клиническая фармакология и терапия. 2016; 25 (3): 90-92.Bochanova E.N., Shnaider N.A., Zyryanov S.K., Dmitrenko D.V., Zhuravlev D.A., Nozdrachev K.G., Bogdanov V.V., Veselova O. F. Estimation of the consumption of antiepileptic drugs in outpatient practice. Klinicheskaya farmakologiya i terapiya (in Russ.). 2016; 25 (3): 90-92.Бочанова Е.Н., Шнайдер Н.А., Зырянов С.К., Гусев С.Д., Насырова Р.Ф. Персонализированный подход к повышению безопасности фармакотерапии эпилепсии. Доктор.Ру. 2018; 153 (9): 13-18. DOI: 10.31550/1727-2378-2018-153-9-13-18.Bochanova E.N., Shnaider N.A., Zyryanov S.K., Gusev S.D., Nasyrova R. F. Personalized approach to increasing the safety of pharmacotherapy for epilepsy. Doktor.Ru. (in Russ.). 2018; 153 (9): 13-18. DOI: 10.31550/1727-2378-2018-153-9-13-18.Бочанова Е.Н., Шнайдер Н.А., Дмитренко Д.В., Артюхов И.П., Гусев С.Д., Зырянов С.К., Насырова Р.Ф. Сравнительная оценка частоты аггравации эпилептических припадков на фоне приема противоэпилептических препаратов различных поколений. Фарматека. 2017; 9: 56-60.Bochanova E.N., Shnaider N.A., Dmitrenko D.V., Artyukhov I.P., Gusev S.D., Zyryanov S.K., Nasyrova R. F. Comparative assessment of the frequency of aggravation of epileptic seizures while taking antiepileptic drugs of various generations. Farmateka. (in Russ.). 2017; 9: 56-60.Бочанова Е.Н., Шнайдер Н.А., Зырянов С.К., Дмитренко Д.В., Шаповалова Е.А., Веселова О.Ф., Шилкина О.С., Журавлев Д.А. Возрастные и гендерные аспекты нежелательных побочных реакций у пациентов с эпилепсией и эпилептическими синдромами (по данным регистра Университетской клиники). Фарматека. 2016; 20 (7): 71-75.Bochanova E.N., Shnaider N.A., Zyryanov S.K., Dmitrenko D.V., Shapovalova E.A., Veselova O. F., Shilkina O.S., Zhuravlev D.A. Age and gender aspects of unwanted adverse reactions in patients with epilepsy and epileptic syndromes (according to the register of the University Hospital). Farmateka (in Russ.). 2016; 20 (7): 71-75.Шнайдер Н.А., Дмитренко Д.В., Пилюгина М.С. Фармакогенетика антиэпилептических препаратов. Бюллетень сибирской медицины. 2008; 4: 111-119.Shnaider N.A., Dmitrenko D.V., Pilyugina M.S. Pharmacogenetics of antiepileptic drugs. Byulleten’ sibirskoi meditsiny (in Russ.). 2008; 4: 111-119.Бочанова Е.Н. Фармакогенетика противоэпилептических препаратов (обзор литературы). Качественная клиническая практика. 2017; 1: 51-57.Bochanova E.N. Pharmacogenetics of antiepileptic drugs (literature review). Kachestvennaya klinicheskaya praktika (in Russ.). 2017; 1: 51-57.Насырова Р.Ф., Сивакова Н.А., Липатова Л.В., Иващенко Д.В., Сосина К.А., Дроков А.П., Шнайдер Н.А. Биологические маркеры эффективности и безопасности противоэпилептических препаратов: фармакогенетика и фармакокинетика. Сибирское медицинское обозрение. 2017; 1: 17-25. DOI: 10.20333/2500136-2017-1-17-25.Nasyrova R. F., Sivakova N.A., Lipatova L.V., Ivashchenko D.V., Sosina K.A., Drokov A.P., Shnaider N.A. Biological markers of the effectiveness and safety of antiepileptic drugs: pharmacogenetics and pharmacokinetics. Sibirskoe meditsinskoe obozrenie (in Russ.). 2017; 1: 17-25. DOI: 10.20333/2500136-2017-1-17-25.Докукина Т.В., Гилеп А.А., Старцев А.И., Голубева Т.С., Махров М.В., Гайдукевич И.В., Марчук С.А., Шеремет Е.А., Усова Н.Н., Королевич П.П., Роменский А.В., Хлебоказов Ф.П. Интерпретация результатов фармакогенетического тестирования у пациентов с психическими и поведенческими расстройствами при назначении психотропных лекарственных средств: учеб.-метод. пособие. Минск. 2016; 54 с.Dokukina T.V., Gilep A.A., Startsev A. I., Golubeva T.S., Makhrov M.V., Gaidukevich I.V., Marchuk S.A., Sheremet E.A., Usova N.N., Korolevich P.P., Romenskii A.V., Khlebokazov F.P. Interpretation of the results of pharmacogenetic testing in patients with mental and behavioral disorders when prescribing psychotropic drugs: a training manual. Minsk. 2016; 54 s.Ambrósio A. F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002; 27 (1-2): 121-30. DOI: 10.1023/a:1014814924965.Ambrósio A. F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002; 27 (1-2): 121-30. DOI: 10.1023/a:1014814924965Stahl S.M. Stahl’s essential psychopharmacology: Neuroscientific Basis and Practical Applications (3rdedn.) 2008. Cambrigde University Press, New York.Stahl S.M. Stahl’s essential psychopharmacology: Neuroscientific Basis and Practical Applications (3rdedn.) 2008. Cambrigde University Press, New York.Sadock B. J., Sadock V.A., Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry (9thedn.) 2009. Lippincott Williams & Wilkins, Philadelphia.Sadock B. J., Sadock V.A., Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry (9thedn.) 2009. Lippincott Williams & Wilkins, Philadelphia.Stahl S.M. Stahl’s essential psychopharmacology: Neuroscientific Basis and Practical Applications (3rdedn.) 2008. Cambrigde University Press, New York.Stahl S.M. Stahl’s essential psychopharmacology: Neuroscientific Basis and Practical Applications (3rdedn.) 2008. Cambrigde University Press, New York.Ambrósio A. F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002; 27 (1-2): 121-30. DOI: 10.1023/a:1014814924965.Ambrósio A. F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002; 27 (1-2): 121-30. DOI: 10.1023/a:1014814924965.Sadock B. J., Sadock V.A., Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry (9thedn.) 2009. Lippincott Williams & Wilkins, Philadelphia.Sadock B. J., Sadock V.A., Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry (9thedn.) 2009. Lippincott Williams & Wilkins, Philadelphia.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729-744. DOI: 10.1007/s13318-016-0397-3.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729-744. DOI: 10.1007/s13318-016-0397-3.Arvidsson J., Nilsson H. L., Sandstedt P., et al. Replacing carbamazepine slow-release tablets with carbamazepine suppositories: a pharmacokinetic and clinical study in children with epilepsy. J Child Neurol. 1995; 10 (2): 114-117. DOI: 10.1177/088307389501000209.Arvidsson J., Nilsson H. L., Sandstedt P., et al. Replacing carbamazepine slow-release tablets with carbamazepine suppositories: a pharmacokinetic and clinical study in children with epilepsy. J Child Neurol. 1995; 10 (2): 114-117. DOI: 10.1177/088307389501000209.Miles M.V., Lawless S. T., Tennison M.B., et al. Rapid loading of critically ill patients with carbamazepine suspension. Pediatrics. 1990; 86 (2): 263-266.Miles M.V., Lawless S. T., Tennison M.B., et al. Rapid loading of critically ill patients with carbamazepine suspension. Pediatrics. 1990; 86 (2): 263-266.Milovanovic J.R., Jankovic S.M. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2011; 49 (7): 428-436. DOI: 10.5414/cp201517.Milovanovic J.R., Jankovic S.M. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2011; 49 (7): 428-436. DOI: 10.5414/cp201517.Carlsson K.C., Hoem N.O., Glauser T., Vinks A.A. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Clin Ther. 2005; 27 (5): 618-626. DOI: 10.1016/j.clinthera.2005.05.001.Carlsson K.C., Hoem N.O., Glauser T., Vinks A.A. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Clin Ther. 2005; 27 (5): 618-626. DOI: 10.1016/j.clinthera.2005.05.001.Summers B., Summers R.S. Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and comedication. Clin Pharmacokinet. 1989; 17 (3): 208-216.Summers B., Summers R.S. Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and comedication. Clin Pharmacokinet. 1989; 17 (3): 208-216.Hartley R., Forsythe W. I., McLain B., et al. Daily variations in steadystate plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet. 1991; 20 (3): 237-46.Hartley R., Forsythe W. I., McLain B., et al. Daily variations in steadystate plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet. 1991; 20 (3): 237-46.Paxton J.W., Aman M.G., Werry J.S. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. Epilepsia. 1983; 24 (6): 716-724.Paxton J.W., Aman M.G., Werry J.S. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. Epilepsia. 1983; 24 (6): 716-724.Emich-Widera E., Likus W., Kazek B., et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013; 2013: 526837. DOI: 10.1155/2013/526837.Emich-Widera E., Likus W., Kazek B., et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013; 2013: 526837. DOI: 10.1155/2013/526837.Ufer M., von Stulpnagel C., Muhle H., et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011; 21 (10): 624-630. DOI: 10.1097/FPC.0b013e3283498131.Ufer M., von Stulpnagel C., Muhle H., et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011; 21 (10): 624-630. DOI: 10.1097/FPC.0b013e3283498131.Pearce R. E., Lu W., Wang Y.Q., Uetrecht J.P., Correia M.A., Leeder J.S. Pathways of сarbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metabolism and Disposition. August 2008; 36 (8): 1637-1649. DOI: 10.1124/dmd.107.019562.Pearce R. E., Lu W., Wang Y.Q., Uetrecht J.P., Correia M.A., Leeder J.S. Pathways of sarbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metabolism and Disposition. August 2008; 36 (8): 1637-1649. DOI: 10.1124/dmd.107.019562.Kerr B.M., Thummel K. E., Wurden C. J., et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994; 47 (11): 1969- 1979.Kerr B.M., Thummel K.E., Wurden C.J., et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994; 47 (11): 1969-1979.Pelkonen O., Myllynen P., Taavitsainen P., et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica. 2001; 31 (6): 321-343. DOI: 10.1080/00498250110055479.Pelkonen O., Myllynen P., Taavitsainen P., et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica. 2001; 31 (6): 321-343. DOI: 10.1080/00498250110055479.Kang P., Liao M., Wester M.R., et al. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos. 2008; 36 (3): 490-499. DOI: 10.1124/dmd.107.016501.Kang P., Liao M., Wester M.R., et al. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos. 2008; 36 (3): 490-499. DOI: 10.1124/dmd.107.016501.Shakya G., Malla S., Shakya K.N., Shrestha R. Therapeutic drug monitoring of antiepileptic drugs. JNMA J Nepal Med Assoc. 2008; 47 (171): 94-7.Shakya G., Malla S., Shakya K.N., Shrestha R. Therapeutic drug monitoring of antiepileptic drugs. JNMA J Nepal Med Assoc. 2008; 47 (171): 94-7.Дмитренко Д.В., Шнайдер Н.А., Бочанова Е.Н., Артюхов И.П., Зырянов С.К., Веселова О.Ф., Гусев С.Д., Потупчик Т.В. Терапевтический лекарственный мониторинг в лечении эпилепсии. Врач. 2017; 1: 81-83.Dmitrenko D.V., Shnaider N.A., Bochanova E.N., Artyukhov I.P., Zyryanov S.K., Veselova O. F., Gusev S.D., Potupchik T.V. Therapeutic drug monitoring in the treatment of epilepsy. Vrach (in Russ). 2017; 1: 81-83.Насырова Р.Ф., Иванов М.В., Незнанов Н. Г. Введение в психофармакогенетику. СПб. 2015; 272 с.Nasyrova R. F., Ivanov M.V., Neznanov N.G. Introduction to psychopharmacogenetics. SPb. 2015; 272 s. (in Russ).Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. NeuroReport. 2001; 12 (16): 3557-60. DOI: 10.1097/00001756-200111160-00037.Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. NeuroReport. 2001; 12 (16): 3557-60. DOI: 10.1097/00001756-200111160-00037.Аксенова М. Г., Качалин Е.Ю., Бурд С. Г., Авакян Г.Н., Бадалян О.Л., Савенков А.А., Тертышник О.Ю., Дорофеева М.Ю., Белоусова Е.Д., Гусев Е.И. Связь полиморфизма С3435 гена MDR1 с эффективностью действия карбамазепинов. Медицинская генетика. 2007; 6 (10): 39-41.Aksenova M.G., Kachalin E. Yu., Burd S.G., Avakyan G.N., Badalyan O. L., Savenkov A.A., Tertyshnik O. Yu., Dorofeeva M. Yu., Belousova E.D., Gusev E. I. Relationship between the C3435 polymorphism of the MDR1 gene and the effectiveness of carbamazepines. Meditsinskaya genetika (in Russ). 2007; 6 (10): 39-41.Emich-Widera E., Likus W., Kazek B., et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013; 2013: 526837. DOI: 10.1155/2013/526837.Emich-Widera E., Likus W., Kazek B., et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013; 2013: 526837. DOI: 10.1155/2013/526837.Kim W. J., Lee J.H., Yi J., et al. A nonsynonymous variation in MRP2/ ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010; 20 (4): 249-256. DOI: 10.1097/FPC.0b013e328338073a.Kim W. J., Lee J.H., Yi J., et al. A nonsynonymous variation in MRP2/ ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010; 20 (4): 249-256. DOI: 10.1097/FPC.0b013e328338073a.Pelkonen O., Myllynen P., Taavitsainen P., et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica. 2001; 31 (6): 321-343. DOI: 10.1080/00498250110055479.Pelkonen O., Myllynen P., Taavitsainen P., et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica. 2001; 31 (6): 321-343. DOI: 10.1080/00498250110055479.Thorn C. F., Leckband S.G., Kelsoe J., et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics. 2011; 21 (12): 906-910. DOI: 10.1097/FPC.0b013e328348c6f2.Thorn C. F., Leckband S.G., Kelsoe J., et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics. 2011; 21 (12): 906-910. DOI: 10.1097/FPC.0b013e328348c6f2.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729-744. DOI: 10.1007/s13318-016-0397-3.Djordjevic N., Jankovic S.M., Milovanovic J.R. Pharmacokinetics and pharmacogenetics of carbamazepine in children. European Journal of Drug Metabolism and Pharmacokinetics. 2017; 42 (5): 729-744. DOI: 10.1007/s13318-016-0397-3.Sadee W. The relevance of “missing heritability“ in pharmacogenomics. Clin Pharmacol Ther. 2012; 92 (4): 428-430. DOI: 10.1038/clpt.2012.116.Sadee W. The relevance of “missing heritability“ in pharmacogenomics. Clin Pharmacol Ther. 2012; 92 (4): 428-430. DOI: 10.1038/clpt.2012.116.Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138: 103-141. DOI: 10.1016/j.pharmthera.2012.12.007.Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138: 103-141. DOI: 10.1016/j.pharmthera.2012.12.007.Maekawa K., Yoshimura T., Saito Y., Fujimura Y., Aohara F., Emoto C., Iwasaki K., Hanioka N., Narimatsu S., Niwa T., Sawada J. in Xenobiotica; the fate of foreign compounds in biological systems (2009) PMID: 19255940 (opens in new window) DOI: 10.1080/00498250802617746.Maekawa K., Yoshimura T., Saito Y., Fujimura Y., Aohara F., Emoto C., Iwasaki K., Hanioka N., Narimatsu S., Niwa T., Sawada J. in Xenobiotica; the fate of foreign compounds in biological systems (2009) PMID: 19255940 (opens in new window) DOI: 10.1080/00498250802617746.Maekawa Keiko, Harakawa Noriko, Yoshimura Takuya, Kim Su-Ryang, Fujimura Yoshiyuki, Aohara Fumika, Sai Kimie, Katori Noriko, Tohkin Masahiro, Naito Mikihiko, Hasegawa Ryuichi, Okuda Haruhiro, Sawada Jun-ichi, Niwa Takuro, Saito Yoshiro in Drug metabolism and disposition: the biological fate of chemicals. 2010; DOI: 10.1124/dmd.110.034140.Maekawa Keiko, Harakawa Noriko, Yoshimura Takuya, Kim Su-Ryang, Fujimura Yoshiyuki, Aohara Fumika, Sai Kimie, Katori Noriko, Tohkin Masahiro, Naito Mikihiko, Hasegawa Ryuichi, Okuda Haruhiro, Sawada Jun-ichi, Niwa Takuro, Saito Yoshiro in Drug metabolism and disposition: the biological fate of chemicals. 2010; DOI: 10.1124/ dmd.110.034140Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11: 773-779.Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11: 773-779. DOI: 10.1038/86882.Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27: 383-391. DOI: 10.1038/86882.Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27: 383-391. DOI: 10.1038/86882.Saruwatari J., Yoshida S., Tsuda Y., et al. Pregnane X receptor and hepatocyte nuclear factor 4alpha polymorphisms are cooperatively associated with carbamazepine autoinduction. Pharmacogenet Genomics. 2014; 24 (3): 162-171. DOI: 10.1097/FPC.0000000000000030.Saruwatari J., Yoshida S., Tsuda Y., et al. Pregnane X receptor and hepatocyte nuclear factor 4alpha polymorphisms are cooperatively associated with carbamazepine autoinduction. Pharmacogenet Genomics. 2014; 24 (3): 162-171. DOI: 10.1097/ FPC.0000000000000030.Dragas Milovanovic D, Radosavljevic I, Radovanovic M, et al. CYP3A5 polymorphism in Serbian paediatric epileptic patients on carbamazepine treatment. SJECR. 2015; 16 (2): 93-99.Dragas Milovanovic D, Radosavljevic I, Radovanovic M, et al. CYP3A5 polymorphism in Serbian paediatric epileptic patients on carbamazepine treatment. SJECR. 2015; 16 (2): 93-99.Pearce R. E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 2002; 30 (11): 1170-1179. DOI: 10.1124/dmd.30.11.1170.Pearce R. E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 2002; 30 (11): 1170-1179. DOI: 10.1124/dmd.30.11.1170.Gao Y., Liu D., Wang H., et al. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica. 2010; 40 (7): 467-475. DOI: 10.3109/00498254.2010.487163.Gao Y., Liu D., Wang H., et al. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica. 2010; 40 (7): 467-475. DOI: 10.3109/00498254.2010.487163.Ferguson S.S., Chen Y., LeCluyse E.L., et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005; 68 (3): 747-757. DOI: 10.1124/mol.105.013169.Ferguson S.S., Chen Y., LeCluyse E.L., et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005; 68 (3): 747-757. DOI: 10.1124/mol.105.013169.Dragas Milovanovic D., Milovanovic J.R., Radovanovic M., et al. The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients. BJMG. 2016; 19 (1): 21-28. DOI: 10.1515/ bjmg-2016-0003.Dragas Milovanovic D., Milovanovic J.R., Radovanovic M., et al. The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients. BJMG. 2016; 19 (1): 21-28. DOI: 10.1515/ bjmg-2016-0003.Aklillu E., Carrillo J.A., Makonnen E., et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64 (3): 659-669. DOI: 10.1124/mol.64.3.659.Aklillu E., Carrillo J.A., Makonnen E., et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64 (3): 659-669. DOI: 10.1124/mol.64.3.659.Sim S.C., Risinger C., Dahl M. L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79 (1): 103-113. DOI: 10.1016/j. clpt.2005.10.002.Sim S.C., Risinger C., Dahl M. L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79 (1): 103-113. DOI: 10.1016/j. clpt.2005.10.002.Aklillu E., Carrillo J.A., Makonnen E., et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64 (3): 659-669. DOI: 10.1124/mol.64.3.659.Aklillu E., Carrillo J.A., Makonnen E., et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64 (3): 659-669. DOI: 10.1124/mol.64.3.659.Djordjevic N., Ghotbi R., Jankovic S., Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism. Eur J Clin Pharmacol. 2010; 66: 697-703. DOI: 10.1007/ s00228-010-0823-4.Djordjevic N., Ghotbi R., Jankovic S., Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism. Eur J Clin Pharmacol. 2010; 66: 697-703. DOI: 10.1007/ s00228-010-0823-4.Pharm G.K.B. Carbamazepine Pathway, Pharmacokinetics ttps://www. pharmgkb.org/pathway/PA165817070 (дата обращения 28.07.2019)PharmGKB. Carbamazepine Pathway, Pharmacokinetics ttps://www. pharmgkb.org/pathway/PA165817070 Accessed 28.07.2019Shakya G., Malla S., Shakya K.N., Shrestha R. Therapeutic drug monitoring of antiepileptic drugs. JNMA J Nepal Med Assoc. 2008; 47 (171): 94-97.Shakya G., Malla S., Shakya K.N., Shrestha R. Therapeutic drug monitoring of antiepileptic drugs. JNMA J Nepal Med Assoc. 2008; 47 (171): 94-97.Pirmohamed M., Friedmann P.S., Molokhia M., Loke Y.K., Smith C., Phillips E., La Grenade L., Carleton B., Papaluca-Amati M., Demoly P., Shear N.H. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011; 89 (6): 896-901. DOI: 10.1038/clpt.2011.79.Pirmohamed M., Friedmann P.S., Molokhia M., Loke Y.K., Smith C., Phillips E., La Grenade L., Carleton B., Papaluca-Amati M., Demoly P., Shear N.H. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011; 89 (6): 896-901. DOI: 10.1038/clpt.2011.79.Yip V. L., Marson A.G., Jorgensen A. L., Pirmohamed M., Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012; 92 (6): 757-765. DOI: 10.1038/clpt.2012.189.Yip V. L., Marson A.G., Jorgensen A. L., Pirmohamed M., Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012; 92 (6): 757-765. DOI: 10.1038/clpt.2012.189.Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994; 331 (19): 1272-1285. DOI: 10.1056/ NEJM199411103311906.Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994; 331 (19): 1272-1285. DOI: 10.1056/ NEJM199411103311906.Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004; 114 (5): 1209-15. DOI: 10.1016/j.jaci.2004.07.047.Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004; 114 (5): 1209-15. DOI: 10.1016/j.jaci.2004.07.047.Naisbitt D. J., Britschgi M., Wong G., Farrell J., Depta J.P., Chadwick D.W., Pichler W. J., Pirmohamed M., Park B.K. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003; 63 (3): 732-741. DOI: 10.1124/mol.63.3.732.Naisbitt D. J., Britschgi M., Wong G., Farrell J., Depta J.P., Chadwick D.W., Pichler W. J., Pirmohamed M., Park B.K. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003; 63 (3): 732-741. DOI: 10.1124/mol.63.3.732.Pichler W. J., Beeler A., Keller M., Lerch M., Posadas S., Schmid D., Spanou Z., Zawodniak A., Gerber B. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006; 55 (1): 17-25. DOI: 10.2332/allergolint.55.17.Pichler W. J., Beeler A., Keller M., Lerch M., Posadas S., Schmid D., Spanou Z., Zawodniak A., Gerber B. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006; 55 (1): 17-25. DOI: 10.2332/allergolint.55.17.Wei C.Y., Chung W.H., Huang H.W., Chen Y. T., Hung S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012; 129 (6): 1562-9.e5. DOI: 10.1016/j.jaci.2011.12.990.Wei C.Y., Chung W.H., Huang H.W., Chen Y. T., Hung S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012; 129 (6): 1562-9.e5. DOI: 10.1016/j.jaci.2011.12.990.Bloch K.M., Sills G. J., Pirmohamed M., Alfirevic A. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics. 2014; 15 (6): 857-68. DOI: 10.2217/pgs.14.65.Bloch K.M., Sills G. J., Pirmohamed M., Alfirevic A. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics. 2014; 15 (6): 857-68. DOI: 10.2217/pgs.14.65.Leckband S.G., Kelsoe J.R., Dunnenberger H.M., George A. L. Jr, Tran E., Berger R., Müller D. J., Whirl-Carrillo M., Caudle K. E., Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013; 94 (3): 324-8. DOI: 10.1038/clpt.2013.103.Leckband S.G., Kelsoe J.R., Dunnenberger H.M., George A. L. Jr, Tran E., Berger R., Müller D. J., Whirl-Carrillo M., Caudle K. E., Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013; 94 (3): 324-8. DOI: 10.1038/clpt.2013.103.Chung W.H., Hung S. I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., Wu J.Y., Chen Y. T. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428 (6982): 486. DOI: 10.1038/428486a.Chung W.H., Hung S. I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., Wu J.Y., Chen Y. T. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428 (6982): 486. DOI: 10.1038/428486a.Man C.B., Kwan P., Baum L., Yu E., Lau K.M., Cheng A.S., Ng M.H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48 (5): 1015-1018. DOI: 10.1111/j.1528-1167.2007.01022.x.Man C.B., Kwan P., Baum L., Yu E., Lau K.M., Cheng A.S., Ng M.H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48 (5): 1015-1018. DOI: 10.1111/j.1528-1167.2007.01022.x.Wu X. T., Hu F.Y., An D.M., Yan B., Jiang X., Kwan P., Stefan H., Zhou D. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 2010; 19 (3): 405-408. DOI: 10.1016/j. yebeh.2010.08.007.Wu X. T., Hu F.Y., An D.M., Yan B., Jiang X., Kwan P., Stefan H., Zhou D. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 2010; 19 (3): 405-408. DOI: 10.1016/j. yebeh.2010.08.007.Wang Q., Zhou J.Q., Zhou L.M., Chen Z.Y., Fang Z.Y., Chen S.D., Yang L.B., Cai X.D., Dai Q. L., Hong H., Wang H.X. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011; 20 (6): 446-448. DOI: 10.1016/j.seizure.2011.02.003.Wang Q., Zhou J.Q., Zhou L.M., Chen Z.Y., Fang Z.Y., Chen S.D., Yang L.B., Cai X.D., Dai Q. L., Hong H., Wang H.X. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011; 20 (6): 446-448. DOI: 10.1016/j.seizure.2011.02.003.Shi Y.W., Min F. L., Qin B., Zou X., Liu X.R., Gao M.M., Wang Q., Zhou J.Q., Liao W.P. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012; 111 (1): 58-64. DOI: 10.1111/j.1742-7843.2012.00868.x.Shi Y.W., Min F. L., Qin B., Zou X., Liu X.R., Gao M.M., Wang Q., Zhou J.Q., Liao W.P. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012; 111 (1): 58-64. DOI: 10.1111/j.1742-7843.2012.00868.x.Amstutz U., Ross C. J., Castro-Pastrana L.I., Rieder M. J., Shear N.H., Hayden M.R., Carleton B.C. CPNDS Consortium. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013; 94 (1): 142-149. DOI: 10.1038/ clpt.2013.55.Amstutz U., Ross C. J., Castro-Pastrana L.I., Rieder M. J., Shear N.H., Hayden M.R., Carleton B.C. CPNDS Consortium. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013; 94 (1): 142-149. DOI: 10.1038/ clpt.2013.55.Tangamornsuksan W., Chaiyakunapruk N., Somkrua R., Lohitnavy M., Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149 (9): 1025-1032. DOI: 10.1001/ jamadermatol.2013.4114.Tangamornsuksan W., Chaiyakunapruk N., Somkrua R., Lohitnavy M., Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149 (9): 1025-1032. DOI: 10.1001/ jamadermatol.2013.4114.Grover S., Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics. 2014; 24 (2): 94-112. DOI: 10.1097/ FPC.0000000000000021.Grover S., Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics. 2014; 24 (2): 94-112. DOI: 10.1097/ FPC.0000000000000021.Khor A.H., Lim K.S., Tan C. T., Wong S.M., Ng C.C. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia. 2014; 55 (11): e120-4. DOI: 10.1111/epi.12802.Khor A.H., Lim K.S., Tan C. T., Wong S.M., Ng C.C. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia. 2014; 55 (11): e120-4. DOI: 10.1111/epi.12802.Chen P., Lin J. J., Lu C.S., Ong C. T., Hsieh P. F., Yang C.C., Tai C. T., Wu S. L., Lu C.H., Hsu Y.C., Yu H.Y., Ro L.S., Lu C. T., Chu C.C., Tsai J. J., Su Y.H., Lan S.H., Sung S. F., Lin S.Y., Chuang H.P., Huang L.C., Chen Y. J., Tsai P. J., Liao H. T., Lin Y.H., Chen C.H., Chung W.H., Hung S. I., Wu J.Y., Chang C. F., Chen L., Chen Y. T., Shen C.Y. Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011; 364 (12): 1126-1133. DOI: 10.1056/NEJMoa1009717.Chen P., Lin J. J., Lu C.S., Ong C. T., Hsieh P. F., Yang C.C., Tai C. T., Wu S. L., Lu C.H., Hsu Y.C., Yu H.Y., Ro L.S., Lu C. T., Chu C.C., Tsai J. J., Su Y.H., Lan S.H., Sung S. F., Lin S.Y., Chuang H.P., Huang L.C., Chen Y. J., Tsai P. J., Liao H. T., Lin Y.H., Chen C.H., Chung W.H., Hung S. I., Wu J.Y., Chang C. F., Chen L., Chen Y. T., Shen C.Y. Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011; 364 (12): 1126-1133. DOI: 10.1056/NEJMoa1009717.Puangpetch A., Koomdee N., Chamnanphol M., Jantararoungtong T., Santon S., Prommas S., Hongkaew Y., Sukasem C. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front Genet. 2015; 5: 478. DOI: 10.3389/fgene.2014.00478.Puangpetch A., Koomdee N., Chamnanphol M., Jantararoungtong T., Santon S., Prommas S., Hongkaew Y., Sukasem C. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front Genet. 2015; 5: 478. DOI: 10.3389/fgene.2014.00478.Alfirevic A., Jorgensen A. L., Williamson P.R., Chadwick D.W., Park B.K., Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006; 7 (6): 813-818. DOI: 10.2217/14622416.7.6.813.Alfirevic A., Jorgensen A. L., Williamson P.R., Chadwick D.W., Park B.K., Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006; 7 (6): 813-818. DOI: 10.2217/14622416.7.6.813.Lonjou C., Borot N., Sekula P., Ledger N., Thomas L., Halevy S, Naldi L., Bouwes-Bavinck J.N., Sidoroff A., de Toma C., Schumacher M., Roujeau J.C., Hovnanian A., Mockenhaupt M. RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008; 18 (2): 99-107. DOI: 10.1097/FPC.0b013e3282f3ef9c.Lonjou C., Borot N., Sekula P., Ledger N., Thomas L., Halevy S, Naldi L., Bouwes-Bavinck J.N., Sidoroff A., de Toma C., Schumacher M., Roujeau J.C., Hovnanian A., Mockenhaupt M. RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008; 18 (2): 99-107. DOI: 10.1097/FPC.0b013e3282f3ef9c.Chen Z., Liew D., Kwan P. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014; 83 (22): 2077-2084. DOI: 10.1212/WNL.0000000000001034.Chen Z., Liew D., Kwan P. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014; 83 (22): 2077-2084. DOI: 10.1212/WNL.0000000000001034.Hung S. I., Chung W.H., Jee S.H., Chen W.C., Chang Y. T., Lee W.R., Hu S. L., Wu M.T, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang Y.L, Lin J. J., Chen Y. T. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006; 16 (4): 297-306. DOI: 10.1097/01.fpc.0000199500.46842.4a.Hung S. I., Chung W.H., Jee S.H., Chen W.C., Chang Y. T., Lee W.R., Hu S. L., Wu M.T, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang Y.L, Lin J. J., Chen Y. T. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006; 16 (4): 297-306. DOI: 10.1097/01.fpc.0000199500.46842.4a.Mizumoto K., Sumikawa Y., Niihara H., Morita E. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol. 2012; 39 (9): 791-792. DOI: 10.1111/j.1346-8138.2011.01421.x.Mizumoto K., Sumikawa Y., Niihara H., Morita E. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol. 2012; 39 (9): 791-792. DOI: 10.1111/j.1346-8138.2011.01421.x.Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., Ikezawa Z., Iijima M., Shiohara T., Hashimoto K., Kamatani N., Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011; 20 (5): 1034-1041. DOI: 10.1093/hmg/ddq537.Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., Ikezawa Z., Iijima M., Shiohara T., Hashimoto K., Kamatani N., Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011; 20 (5): 1034-1041. DOI: 10.1093/hmg/ddq537.Niihara H., Kakamu T., Fujita Y., Kaneko S., Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012; 39 (7): 594-601. DOI: 10.1111/j.1346-8138.2011.01457.x.Niihara H., Kakamu T., Fujita Y., Kaneko S., Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012; 39 (7): 594-601. DOI: 10.1111/j.1346-8138.2011.01457.x.Amstutz U., Ross C. J., Castro-Pastrana L.I., Rieder M. J., Shear N.H., Hayden M.R., Carleton B.C. CPNDS Consortium. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013; 94 (1): 142-149. DOI: 10.1038/ clpt.2013.55.Amstutz U., Ross C. J., Castro-Pastrana L.I., Rieder M. J., Shear N.H., Hayden M.R., Carleton B.C. CPNDS Consortium. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013; 94 (1): 142-149. DOI: 10.1038/ clpt.2013.55.McCormack M., Alfirevic A., Bourgeois S., Farrell J. J., Kasperavičiūtė D., Carrington M., Sills G. J., Marson T., Jia X., de Bakker P. I., Chinthapalli K., Molokhia M., Johnson M.R., O’Connor G.D., Chaila E., Alhusaini S., Shianna K.V., Radtke R.A., Heinzen E. L., Walley N., Pandolfo M., Pichler W., Park B.K., Depondt C., Sisodiya S.M., Goldstein D.B., Deloukas P., Delanty N., Cavalleri G. L., Pirmohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364 (12): 1134-1143. DOI: 10.1056/NEJMoa1013297.McCormack M., Alfirevic A., Bourgeois S., Farrell J. J., Kasperavičiūtė D., Carrington M., Sills G. J., Marson T., Jia X., de Bakker P. I., Chinthapalli K., Molokhia M., Johnson M.R., O’Connor G.D., Chaila E., Alhusaini S., Shianna K.V., Radtke R.A., Heinzen E. L., Walley N., Pandolfo M., Pichler W., Park B.K., Depondt C., Sisodiya S.M., Goldstein D.B., Deloukas P., Delanty N., Cavalleri G. L., Pirmohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364 (12): 1134-1143. DOI: 10.1056/NEJMoa1013297.Genin E., Chen D.P., Hung S. I., Sekula P., Schumacher M., Chang P.Y., Tsai S.H., Wu T. L., Bellón T., Tamouza R., Fortier C., Toubert A., Charron D., Hovnanian A., Wolkenstein P., Chung W.H., Mockenhaupt M., Roujeau J.C. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014; 14 (3): 281-288. DOI: 10.1038/tpj.2013.40.Genin E., Chen D.P., Hung S. I., Sekula P., Schumacher M., Chang P.Y., Tsai S.H., Wu T. L., Bellón T., Tamouza R., Fortier C., Toubert A., Charron D., Hovnanian A., Wolkenstein P., Chung W.H., Mockenhaupt M., Roujeau J.C. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014; 14 (3): 281-288. DOI: 10.1038/tpj.2013.40.Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., Furuya H., Takahashi Y., Muramatsu M., Kinoshita S., Abe M., Ikeda H., Kashiwagi M., Song Y., Ueta M., Sotozono C., Ikezawa Z., Hasegawa R. JSAR research group. HLA-B*1511 is a risk factor for carbamazepineinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010; 51 (12): 2461-2465. DOI: 10.1111/j.1528-1167.2010.02766.x.Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., Furuya H., Takahashi Y., Muramatsu M., Kinoshita S., Abe M., Ikeda H., Kashiwagi M., Song Y., Ueta M., Sotozono C., Ikezawa Z., Hasegawa R. JSAR research group. HLA-B*1511 is a risk factor for carbamazepineinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010; 51 (12): 2461-2465. DOI: 10.1111/j.1528-1167.2010.02766.x.Kim S.H., Lee K.W., Song W. J., Kim S.H., Jee Y.K., Lee S.M., Kang H.R., Park H.W., Cho S.H., Park S.H., Min K.U., Chang Y.S. Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011; 97 (1-2): 190-197. DOI: 10.1016/j.eplepsyres.2011.08.010.Kim S.H., Lee K.W., Song W. J., Kim S.H., Jee Y.K., Lee S.M., Kang H.R., Park H.W., Cho S.H., Park S.H., Min K.U., Chang Y.S. Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011; 97 (1-2): 190-197. DOI: 10.1016/j.eplepsyres.2011.08.010.Holland K.D., Kearney J.A., Glauser T.A., et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett. 2008; 433 (1): 65-70. DOI: 10.1016/j.neulet.2007.12.064.Holland K.D., Kearney J.A., Glauser T.A., et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett. 2008; 433 (1): 65-70. DOI: 10.1016/j.neulet.2007.12.064.Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. British Journal of Clinical Pharmacology. 2008; 66 (2): 304-307. DOI: 10.1111/j.1365-2125.2008.03203.x.Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. British Journal of Clinical Pharmacology. 2008; 66 (2): 304-307. DOI: 10.1111/j.1365-2125.2008.03203.x.Daci A., Beretta G., Vilasaliu D., Shala A., Govori V., Norata G.D., Krasniqi S. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLOS. 2015; DOI: https://doi.org/10.1371/journal. pone.0142408.Daci A., Beretta G., Vilasaliu D., Shala A., Govori V., Norata G.D., Krasniqi S. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLOS. 2015; DOI: https://doi.org/10.1371/journal. pone.0142408.Авакян Г.Н., Бурд С. Г. Современный взгляд на применение пролонгированной формы карбамазепина. Эпилепсия и пароксизмальные состояния. 2012; 4 (2): 67-71.Avakyan G.N., Burd S.G. Modern view on carbamazepine prolonged dosage forms usage in patients with epilepsy (literature review). Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions (in Russ). 2012; 4 (2): 67-71.Государственный реестр лекарственных средств. URL: https://grls. rosminzdrav.ru. Дата обращения: 28.07.2019.State Register of Medicines. URL: https://grls.rosminzdrav.ru. Accessed: 28.07.2019.

The authors declare that there are no conflicts of interest present.